As the RespiriTB Consortium approaches the conclusion of its project timeline, we invite you to a dedicated stakeholder webinar on 23 June 2026 at 15:30 CEST.
This event will spotlight the consortium’s most impactful scientific and translational achievements—delivering new tools, new evidence, and new opportunities for the global TB community.
Beyond celebrating results, the webinar aims to initiate a dialogue on maximizing the real‑world impact of these outputs: How can we accelerate uptake? How can we strengthen links with policymakers? And how can our scientific advances translate into better outcomes for patients, clinicians, and public health programs?
The webinar is open to all stakeholders across the AMR ecosystem, including:
- Scientific and research community
- Patient organizations
- Biotech and pharmaceutical industries
- Public health and AMR-focused organizations
- Policy and advocacy groups
- EMA representatives
Agenda
15:30–15:40 – Welcome & Introduction
- Overview of AMR Accelerator tools & resources
- Introduction to the RespiriTB project
15:40–16:20 – Spotlight on Key Results
Three focused presentations showcasing the consortium’s most impactful scientific and translational outputs
- Bedaquiline Long‑Acting Injectable (BDQ LAI)
Presentation of first‑in‑human pharmacokinetic and safety results for the BDQ LAI formulation, a major step toward simplified and adherence‑friendly TB preventive treatment. - Cytochrome bc₁:aa₃ Inhibitors
CryoEM structures of various cytochrome bc₁:aa₃ inhibitors bound to the protein, providing unique insights into inhibitor mode of action and antibiotic‑resistance‑inducing mutations. - MenG Inhibitors
Insights into the newly characterized mode of action of MenG inhibitors and their ability to resensitize tuberculosis strains resistant to bedaquiline.
16:20–16:40 – Panel Discussion
A discussion featuring consortium leadership and global TB partners on how these scientific outputs can influence future TB strategies, partnerships, and policy decisions.
- Translating RespiriTB Results into Impact: How Can We Reach Policymakers and Drive Adoption?
16:40–17:00 – Audience Q&A
Speakers
- Anna Upton – Evotec, Senior VP, Infectious Diseases
- Meindert Lamers – LUMC, RespiriTB Project Coordinator
- Lluís Ballell – Johnson & Johnson, RespiriTB Project Lead
- Vivian Cox – Johnson & Johnson, Senior Medical Lead, TB
- Clara Aguilar – Johnson & Johnson, Principal Scientist
- Anders Karlén – Uppsala University, AMR Accelerator
- Frederik Deroose – Connecting Pharma, COMBINE Portfolio Manager (Moderator)
(Additional speakers to be confirmed)
Registration
The webinar will be held via GoToMeeting and the link will be send to all registered participants prior to the event. If you want to participate in the webinar, please register via this form:
RespiriTB Stakeholder Webinar 2026: Advancing TB Innovation Through Collaboration
